According to our recent payer coverage analysis for prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for prostate cancer treatments shows that more than 82% of the lives under the medical benefit are covered without utilization management restriction under Medicare policies.

Trends: A U.S. district court ruled that patent claims for Zytiga were invalid. Janssen said it will appeal the decision, but generic versions of the drug could launch at-risk. Via AIS Health.